Barboza-Zanetti Maria Olívia, Barboza-Zanetti Ariane Cristina, Rodrigues-Abjaude Samir Antonio, Pinto-Simões Belinda, Leira-Pereira Leonardo Régis
1 Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, Ribeirão Preto, SP, Brazil.
2 Program in Fundamental Nursing, School of Nursing of Ribeirão Preto, Ribeirão Preto, SP, Brazil.
J Oncol Pharm Pract. 2019 Mar;25(2):423-433. doi: 10.1177/1078155218782372. Epub 2018 Jun 11.
The goal of the present review was to identify studies that assess how pharmaceutical services contribute to hematopoietic stem cell transplantation (HSCT).
We conducted a systematic literature review of published studies describing results from clinical services provided by pharmacists working with HSCT, conducted according to PRISMA guidelines ( PROSPERO registration number CRD42017062391). A search strategy was applied within PubMed, CENTRAL, EMBASE, SCOPUS, and LILACS databases in April 2017. Inclusion criteria were observational or experimental studies that addressed the following research question: "What are a clinical pharmacist's main contributions to HSCT?" The quality of selected studies was evaluated using the Downs and Black checklist.
We identified 1838 studies, and seven were included in the systematic review. The results indicated that clinical pharmacy is useful during HSCT treatment within both inpatient and outpatient settings. Pharmaceutical contributions identified included management of pharmacotherapy-related problems, participation in discussions with clinical teams, drug reconciliation, patient and team education regarding pharmacotherapy, preparation of guidelines and educational materials, and evaluation of medication adherence. These activities favored the control and prevention of pharmacotherapy-related problems, the maintenance of immunosuppressive serum levels, improvement in patients' clinical and nutritional status, facilitated medication adherence, and provided economic and humanistic gains.
Despite the small number of articles discussing the topic under analysis, the results were unanimous in confirming the positive impact of pharmacists' contributions to clinical practice for HSCT.
本综述的目的是识别评估药学服务如何促进造血干细胞移植（HSCT）的研究。
我们根据PRISMA指南（PROSPERO注册号CRD42017062391），对已发表的描述从事HSCT工作的药剂师所提供临床服务结果的研究进行了系统的文献综述。2017年4月在PubMed、CENTRAL、EMBASE、SCOPUS和LILACS数据库中应用了检索策略。纳入标准为解决以下研究问题的观察性或实验性研究：“临床药剂师对HSCT的主要贡献是什么？”使用唐斯和布莱克检查表对所选研究的质量进行评估。
我们识别出1838项研究，其中7项纳入了系统综述。结果表明，临床药学在HSCT治疗的住院和门诊环境中均有用。确定的药学贡献包括药物治疗相关问题的管理、参与与临床团队的讨论、药物重整、对患者和团队进行药物治疗教育、制定指南和教育材料以及评估药物依从性。这些活动有利于控制和预防药物治疗相关问题、维持免疫抑制血清水平、改善患者的临床和营养状况、促进药物依从性，并带来经济和人文效益。
尽管讨论本分析主题的文章数量较少，但结果一致证实了药剂师对HSCT临床实践贡献的积极影响。
